Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The AMPK-related kinase SNARK regulates muscle mass and myocyte survival
Sarah J. Lessard, … , Roger A. Fielding, Laurie J. Goodyear
Sarah J. Lessard, … , Roger A. Fielding, Laurie J. Goodyear
Published December 21, 2015
Citation Information: J Clin Invest. 2016;126(2):560-570. https://doi.org/10.1172/JCI79197.
View: Text | PDF
Research Article Muscle biology Article has an altmetric score of 9

The AMPK-related kinase SNARK regulates muscle mass and myocyte survival

  • Text
  • PDF
Abstract

The maintenance of skeletal muscle mass is critical for sustaining health; however, the mechanisms responsible for muscle loss with aging and chronic diseases, such as diabetes and obesity, are poorly understood. We found that expression of a member of the AMPK-related kinase family, the SNF1-AMPK-related kinase (SNARK, also known as NUAK2), increased with muscle cell differentiation. SNARK expression increased in skeletal muscles from young mice exposed to metabolic stress and in muscles from healthy older human subjects. The regulation of SNARK expression in muscle with differentiation and physiological stress suggests that SNARK may function in the maintenance of muscle mass. Consistent with this hypothesis, decreased endogenous SNARK expression (using siRNA) in cultured muscle cells resulted in increased apoptosis and decreased cell survival under conditions of metabolic stress. Likewise, muscle-specific transgenic animals expressing a SNARK dominant-negative inactive mutant (SDN) had increased myonuclear apoptosis and activation of apoptotic mediators in muscle. Moreover, animals expressing SDN had severe, age-accelerated muscle atrophy and increased adiposity, consistent with sarcopenic obesity. Reduced SNARK activity, in vivo and in vitro, caused downregulation of the Rho kinase signaling pathway, a key mediator of cell survival. These findings reveal a critical role for SNARK in myocyte survival and the maintenance of muscle mass with age.

Authors

Sarah J. Lessard, Donato A. Rivas, Kawai So, Ho-Jin Koh, André Lima Queiroz, Michael F. Hirshman, Roger A. Fielding, Laurie J. Goodyear

×

Figure 3

Generation of muscle-specific SNARK transgenic mice.

Options: View larger image (or click on image) Download as PowerPoint
Generation of muscle-specific SNARK transgenic mice.
(A) Transgenic mice...
(A) Transgenic mice with muscle-specific overexpression of FLAG-tagged wild-type SNARK (SWT) or a dominant-negative inactive SNARK mutant (T208A; SDN) were generated using the MCK promoter. (B) Phosphotransferase activity of SWT and SDN constructs against the AMARA peptide was assessed by immunoprecipitation of FLAG from 293 HEK overexpression lysates using 32P-γ-ATP. n = 5 per group. (C) The dominant-negative nature of the SNARK dominant-negative construct was verified by measuring endogenous SNARK phosphorylation at its activating site T208 in 293 HEK cells transfected with PCDNA3.1 empty vector (EV), SNARK dominant-negative mutant (SDN), or wild-type human SNARK (SWT). n = 4 per group. (D) A FLAG immunoblot demonstrating the expression of SNARK transgene in the TA, extensor digitorum longus (EDL), soleus (SOL), and heart muscles compared with wild-type littermates, and the absence of expression in livers of SNARK transgenic mice. AMPK is shown as a loading control. (E) Relative expression levels of transgene and endogenous protein in the muscles of SNARK transgenic mice and littermate controls using FLAG, phospho-SNARK T208, and total SNARK antibodies. Two lines of transgenic mice overexpressing different levels of dominant-negative SNARK (SDN-Low and SDN-High) were studied, and data from two independent lines of SWT mice with similar expression levels were pooled for analysis. *P < 0.05 vs. control determined by 1-way ANOVA and Bonferroni post-hoc testing. Error bars indicate mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 17 X users
63 readers on Mendeley
See more details